Hépato-Gastro & Oncologie Digestive


Place de la radiothérapie interne vectorisée dans le traitement des tumeurs neuroendocrines Volume 26, supplément 5, Décembre 2019

  • [1] Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017 ; 3 (10) : 1335-1342.
  • [2] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 2017 ; 376 : 125-135.
  • [3] Capello A., Krenning E.P., Breeman W.A.P. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0] octreotide. J Nucl Med. 2003;44:98-104. 1
  • [4] Pool S.E., Krenning E.P., Koning G.A. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med. 2010;40:209-218.
  • [5] Kratochwil C., Stefanova M., Mavriopoulou E. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17:313-318.
  • [6] Ezziddin S., Attassi M., Yong-Hing C.J. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-Octreotate. J Nucl Med. 2014;55:183-190.
  • [7] Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011 ; 29 : 2416-2423.
  • [8] Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep 2017 ; 19:9.
  • [9] Kim S.-J., Pak K., Koo P.J. The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: A meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42:1964-1970.
  • [10] Sabet A., Dautzenberg K., Haslerud T. Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42:1238-1246.
  • [11] Ezziddin S., Khalaf F., Vanezi M. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925-933.
  • [12] Diakatou E., Alexandraki K.I., Tsolakis A.V. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: Correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores. Clin Endocrinol. 2015;83:420-428.
  • [13] Ianniello A., Sansovini M., Severi S. Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: Prognostic role of thyroid transcription factor 1 and 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2016;43:1040-1046.
  • [14] Mariniello A., Bodei L., Tinelli C. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43:441-452.
  • [15] Forrer F., Uusijarvi H., Storch D. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005;46:1310-1316.
  • [16] Severi S, Sansovini M, Ianniello A, et al. Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC. Eur J Nucl Med Mol Imaging 2015 ; 42 : 1955-1963.
  • [17] de Keizer B., van Aken M.O., Feelders R.A. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2008;35:749-755.
  • [18] Bodei L, Kwekkeboom DJ, Kidd M, et al. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med 2016 ; 46 : 225-238.
  • [19] Brieau B., Hentic O., Lebtahi R. High risk of myelodysplastic syndrome and acute myeloid leukemia after Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016;23:L17-L23. 177